INVIVYD INC. - COMMON

0,9213

07-октября-24 14:59:55

15 мин. задержка

Акции

-0,0292

-3,07%

Сегодняшний диапазон

0,9101 - 0,9700

ISIN

N/A

Источник

NASDAQ

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

30 апр 2024 06:30:00 Источник Nasdaq GlobeNewswire
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

15 апр 2024 06:30:00 Источник Nasdaq GlobeNewswire
Invivyd Announces CEO Transition

12 апр 2024 06:30:00 Источник Nasdaq GlobeNewswire
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

04 апр 2024 15:01:00 Источник Nasdaq GlobeNewswire
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

28 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

22 мар 2024 14:28:22 Источник Nasdaq GlobeNewswire
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

22 мар 2024 14:04:58 Источник Nasdaq GlobeNewswire
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

05 фев 2024 15:02:13 Источник Nasdaq GlobeNewswire
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

03 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

18 дек 2023 06:00:00 Источник Nasdaq GlobeNewswire
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

09 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

02 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences

31 окт 2023 15:01:00 Источник Nasdaq GlobeNewswire
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

11 сен 2023 06:00:00 Источник Nasdaq GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences

06 сен 2023 06:00:00 Источник Nasdaq GlobeNewswire
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

10 авг 2023 15:01:00 Источник Nasdaq GlobeNewswire
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

03 авг 2023 15:01:00 Источник Nasdaq GlobeNewswire
Invivyd Announces Appointment of Sara Cotter to Board Of Directors

27 июл 2023 15:01:00 Источник Nasdaq GlobeNewswire
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

17 июл 2023 06:00:00 Источник Nasdaq GlobeNewswire
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

26 июн 2023 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.